MCID: IMP006
MIFTS: 45

Impulse Control Disorder

Categories: Mental diseases

Aliases & Classifications for Impulse Control Disorder

MalaCards integrated aliases for Impulse Control Disorder:

Name: Impulse Control Disorder 12 15
Disruptive, Impulse Control, and Conduct Disorders 43 71

Classifications:



External Ids:

Disease Ontology 12 DOID:10937
ICD9CM 34 312.30
MeSH 43 D007174
NCIt 49 C34723
SNOMED-CT 67 66347000
ICD10 32 F63.9
UMLS 71 C0021122

Summaries for Impulse Control Disorder

Disease Ontology : 12 A disease of mental health that involves a failure to resist an impulsive act or behaviour that may be harmful to self or others.

MalaCards based summary : Impulse Control Disorder, also known as disruptive, impulse control, and conduct disorders, is related to pyromania and trichotillomania. An important gene associated with Impulse Control Disorder is ANKK1 (Ankyrin Repeat And Kinase Domain Containing 1), and among its related pathways/superpathways are Parkinson disease and Beta-Adrenergic Signaling. The drugs Dopamine and Nicotine have been mentioned in the context of this disorder. Affiliated tissues include brain, skin and cortex, and related phenotypes are behavior/neurological and cardiovascular system

Wikipedia : 74 Impulse-control disorder (ICD) is a class of psychiatric disorders characterized by impulsivity -... more...

Related Diseases for Impulse Control Disorder

Diseases related to Impulse Control Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 169)
# Related Disease Score Top Affiliating Genes
1 pyromania 32.7 SLITRK1 RTN4 MAOA DRD2 DNER
2 trichotillomania 32.0 SLITRK5 SLITRK1 HOXB8 DRD4 DRD3 DRD2
3 oppositional defiant disorder 31.6 SLC6A4 SLC6A3 RTN4 MAOA DRD4 DRD2
4 intermittent explosive disorder 31.5 SLITRK1 SLC6A4 MAOA HTR2A HTR1A DRD2
5 kleptomania 31.1 SLITRK1 SLC6A4 RTN4 MAOA HTR1A DRD4
6 withdrawal disorder 30.6 HTR1A DRD2 DRD1
7 avoidant personality disorder 30.4 SLC6A4 SLC6A3 MAOA DRD4
8 hyperprolactinemia 30.2 HTR2A DRD4 DRD2
9 pedophilia 30.1 RTN4 MAOA GRN
10 paraphilia disorder 30.1 RTN4 MAOA GRN
11 multiple system atrophy 1 30.0 SLC6A3 MAOB DRD2
12 eating disorder 30.0 SLC6A4 SLC6A3 HTR2A DRD3 DRD2 COMT
13 sleep disorder 29.8 SLC6A4 SLC6A3 HTR2A HTR1A DRD2
14 bulimia nervosa 29.8 SLC6A4 MAOA HTR2A DRD4 DRD2 COMT
15 depression 29.8 SLC6A4 MAOA HTR2A HTR1A
16 frontotemporal dementia 29.8 SLC6A4 MAOA GRN DRD4
17 fibromyalgia 29.7 SLC6A4 HTR2A HTR1A DRD2 COMT
18 movement disease 29.7 SLC6A3 MAOB GRN DRD5 DRD4 DRD3
19 supranuclear palsy, progressive, 1 29.7 SLC6A3 MAOB GRN DRD5 DRD2
20 premature ejaculation 29.7 SLC6A4 SLC6A3 HTR1A COMT
21 social phobia 29.7 SLC6A4 MAOA HTR1A DRD2 COMT
22 pathological gambling 29.7 SLC6A4 SLC6A3 RTN4 MAOB MAOA HTR2A
23 alexithymia 29.6 SLC6A4 HTR1A DRD2 COMT ANKK1
24 drug dependence 29.6 SLC6A4 SLC6A3 DRD3 DRD2 DRD1 ANKK1
25 agoraphobia 29.5 SLC6A4 MAOA HTR2A HTR1A COMT
26 dysthymic disorder 29.5 SLC6A4 MAOA HTR2A HTR1A
27 phobia, specific 29.4 SLC6A4 RTN4 MAOA HTR1A COMT
28 restless legs syndrome 29.3 SLC6A4 SLC6A3 MAOB MAOA DRD5 DRD4
29 conduct disorder 29.2 SLC6A4 SLC6A3 MAOA DRD5 DRD4 DRD2
30 alcohol use disorder 29.2 SLC6A4 SLC6A3 HTR2A HTR1A DRD3 DRD2
31 anorexia nervosa 29.0 SLC6A4 MAOA HTR2A HTR1A DRD4 COMT
32 borderline personality disorder 28.9 SLC6A4 SLC6A3 MAOA HTR2A HTR1A DRD2
33 dementia 28.9 SLC6A3 MAOB HTR2A HTR1A GRN DRD2
34 generalized anxiety disorder 28.8 SLC6A4 SLC6A3 MAOA HTR2A HTR1A DRD2
35 parkinson disease, late-onset 28.8 SLC6A4 SLC6A3 MAOB MAOA HTR2A HTR1A
36 antisocial personality disorder 28.8 SLC6A4 SLC6A3 RTN4 MAOB MAOA HTR2A
37 bipolar i disorder 28.8 SLC6A4 HTR2A HTR1A DRD4 DRD3 DRD2
38 post-traumatic stress disorder 28.7 SLC6A4 MAOB MAOA HTR2A HTR1A DRD2
39 personality disorder 28.7 SLC6A4 SLC6A3 MAOB MAOA HTR2A HTR1A
40 substance dependence 28.6 SLC6A4 SLC6A3 MAOA DRD5 DRD4 DRD3
41 dystonia 28.6 SLC6A3 MAOB HTR2A GRN DRD5 DRD3
42 mood disorder 28.5 SLC6A4 SLC6A3 MAOB MAOA HTR2A HTR1A
43 substance abuse 28.5 SLC6A4 SLC6A3 RTN4 MAOA HTR2A HTR1A
44 anxiety 28.4 SLC6A4 SLC6A3 MAOB MAOA HTR2A HTR1A
45 bipolar disorder 28.4 SLC6A4 SLC6A3 RTN4 MAOA HTR2A HTR1A
46 tobacco addiction 28.2 SLC6A4 SLC6A3 MAOA HTR2A DRD5 DRD4
47 panic disorder 28.2 SLC6A4 SLC6A3 MAOA HTR2A HTR1A DRD5
48 obsessive-compulsive disorder 28.0 SLITRK5 SLITRK1 SLC6A4 SLC6A3 MAOB MAOA
49 alcohol dependence 28.0 SLC6A4 SLC6A3 MAOB MAOA HTR2A HTR1A
50 attention deficit-hyperactivity disorder 28.0 SLC6A4 SLC6A3 MAOB MAOA HTR2A HTR1A

Comorbidity relations with Impulse Control Disorder via Phenotypic Disease Network (PDN):


Schizophreniform Disorder

Graphical network of the top 20 diseases related to Impulse Control Disorder:



Diseases related to Impulse Control Disorder

Symptoms & Phenotypes for Impulse Control Disorder

MGI Mouse Phenotypes related to Impulse Control Disorder:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.11 COMT DLGAP3 DNER DRD1 DRD2 DRD3
2 cardiovascular system MP:0005385 9.65 COMT DRD1 DRD2 DRD3 DRD5 HTR1A
3 nervous system MP:0003631 9.58 COMT DLGAP3 DNER DRD1 DRD2 DRD3

Drugs & Therapeutics for Impulse Control Disorder

Drugs for Impulse Control Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 79)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
2
Nicotine Approved Phase 4 54-11-5 942 89594
3
Methylphenidate Approved, Investigational Phase 4 113-45-1 4158
4
Levodopa Approved Phase 4 59-92-7 6047
5
Carbidopa Approved Phase 4 28860-95-9 34359
6
Naltrexone Approved, Investigational, Vet_approved Phase 4 16590-41-3 5360515
7
Ropinirole Approved, Investigational Phase 4 91374-20-8, 91374-21-9 497540 5095
8
Pramipexole Approved, Investigational Phase 4 104632-26-0 119570 59868
9
Ethanol Approved Phase 4 64-17-5 702
10
Citalopram Approved Phase 4 59729-33-8 2771
11
Sertraline Approved Phase 4 79617-96-2 68617
12
Guanfacine Approved, Investigational Phase 4 29110-47-2 3519
13
Naratriptan Approved, Investigational Phase 4 121679-13-8, 143388-64-1 4440
14 Central Nervous System Stimulants Phase 4
15 Cholinergic Agents Phase 4
16 Nicotinic Agonists Phase 4
17 Cardiotonic Agents Phase 4
18 Sympathomimetics Phase 4
19 Dopamine Agents Phase 4
20 Aromatic Amino Acid Decarboxylase Inhibitors Phase 4
21 Adrenergic alpha-Agonists Phase 4
22 Antihypertensive Agents Phase 4
23 Adrenergic Agents Phase 4
24 Adrenergic Agonists Phase 4
25 Narcotics Phase 4
26 Narcotic Antagonists Phase 4
27 Psychotropic Drugs Phase 4
28 Antidepressive Agents Phase 4
29 Serotonin Uptake Inhibitors Phase 4
30 Neurotransmitter Agents Phase 4
31 Serotonin 5-HT1 Receptor Agonists Phase 4
32 Vasoconstrictor Agents Phase 4
33 Serotonin Receptor Agonists Phase 4
34
Serotonin Investigational, Nutraceutical Phase 4 50-67-9 5202
35
Risperidone Approved, Investigational Phase 3 106266-06-2 5073
36
Acetylcysteine Approved, Investigational Phase 3 616-91-1 12035
37 Antipsychotic Agents Phase 3
38 Dopamine Antagonists Phase 3
39 N-monoacetylcystine Phase 3
40
Memantine Approved, Investigational Phase 2 19982-08-2 4054
41
Valproic acid Approved, Investigational Phase 2 99-66-1 3121
42
Fluoxetine Approved, Vet_approved Phase 2 54910-89-3 3386
43
Clonidine Approved Phase 2 4205-90-7 2803
44
Pimavanserin Approved, Investigational Phase 2 706779-91-1 16058810
45
Quinidine Approved, Investigational Phase 2 56-54-2 441074
46
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
47
Cysteine Approved, Nutraceutical Phase 2 52-90-4 5862
48 Protective Agents Phase 2
49 Excitatory Amino Acid Antagonists Phase 2
50 Cytochrome P-450 Enzyme Inhibitors Phase 2

Interventional clinical trials:

(show all 41)
# Name Status NCT ID Phase Drugs
1 Methylphenidate Treatment of Children and Adolescents Diagnosed With ADHD and Its Influence on Comorbid Trichotillomania Unknown status NCT00552266 Phase 4 Methylphenidate
2 Nicotine Treatment of Impulsivity in Parkinson's Disease: A Pilot Study Unknown status NCT01216904 Phase 4 nicotine patch;placebo
3 The REmission of the Impulse Control Disorder and the Changes of the Neuropsychiatric Characteristics After Switching Into Levodopa/Carbidopa in Patients With Parkinson's Disease Who Have Developed Impulse Control Disorders Due to the Dopamine Replacement Therapy Completed NCT01683253 Phase 4 Levodopa/Carbidopa(200mg/50mg);Dopaminergic Agonists
4 Randomized, Double-blind, Placebo-controlled Study of Naltrexone for Impulse Control Disorders in Parkinson's Disease Completed NCT01052831 Phase 4 Naltrexone;Placebo
5 Escitalopram for the Treatment of Self-Injurious Skin Picking Completed NCT00115011 Phase 4 Escitalopram
6 Sertraline and Habit Reversal in the Treatment of Patients With Trichotillomania Completed NCT00118014 Phase 4 Sertraline
7 Intuniv vs Placebo in the Treatment of Childhood Intermittent Explosive Disorder Completed NCT02048241 Phase 4 Intuniv
8 Efficacy of a Triptan in the Treatment of Hostility and Aggression Among Convicts With a Psychiatric Treatment Order Terminated NCT00282165 Phase 4 naratriptan;placebo
9 Effects of Risperidone on Cognitive-Motor Performance and Motor Movements in Chronically Medicated Children Completed NCT00399698 Phase 3 Risperdal
10 Study of the Efficacy of N-acetylcysteine (NAC) on Impulse Control Disorders (TCI) Induced by Dopaminergic Treatments in Parkinson's Disease Recruiting NCT03146130 Phase 3
11 Evaluation of Nalmefene in Impulse Control Disorders in Parkinson's Disease: A Prospective Open Label Study Unknown status NCT02934919 Phase 2 Nalmefene
12 A Double-Blind, Placebo-Controlled Study of Naltrexone in Kleptomania Completed NCT00332579 Phase 2 Naltrexone;Placebo
13 Memantine Treatment of Kleptomania: An Open-Label Study Completed NCT00880685 Phase 2 Memantine
14 Fluoxetine and Divalproex: Treatment Correlates in IED Completed NCT00078754 Phase 2 Fluoxetine;Divalproex;Placebo
15 Individual Cognitive Behavioral Psychotherapy for Intermittent Explosive Disorder Completed NCT00667212 Phase 2
16 An Exploratory, Placebo-Controlled, Crossover Study to Examine the Safety and Activity of SXC-2023 to Improve Behavioral Dynamics in Non-Treatment Seeking Adults Undergoing Acute Nicotine Withdrawal Completed NCT03887429 Phase 2 SXC-2023;Placebos
17 A Pilot Study Comparing the Efficacy of Group Versus Individual Anger Management in Subjects With Intermittent Explosive Disorder Completed NCT00127400 Phase 2
18 An Exploratory Phase II Study to Determine the Safety, Tolerability and Activity of a Novel Vasopressin 1a Receptor Antagonist (SRX246) in Adults With Diagnostic and Statistical Manual Version 5 (DSM-5) Intermittent Explosive Disorder (IED) Completed NCT02055638 Phase 1, Phase 2 SRX246;Placebo
19 A Double-Blind, Placebo-Controlled Study of Naltrexone in Compulsive Sexual Behavior Completed NCT00467558 Phase 2 Naltrexone;Sugar pill
20 A Double-Blind, Placebo-Controlled Study of Inositol in Trichotillomania Completed NCT01875445 Phase 2 Inositol;Placebo
21 A Double-Blind, Placebo-Controlled Study of N-Acetyl Cysteine in Pathologic Skin Picking Completed NCT01063348 Phase 2 N-Acetyl Cysteine;Placebo
22 Study of Clonidine Efficacy for the Treatment of Impulse Control Disorders in Parkinson's Disease: A Pilot Double Blind Randomized Trial Recruiting NCT03552068 Phase 2 placebo;Clonidine
23 Study of Pimavanserin Efficacy for the Treatment of Impulse Control Disorders in Parkinson's Disease Recruiting NCT03947216 Phase 2 Active drug: pimavanserin 17mg (2 strength tablets);Placebo: 2 tablets containing same excipients except active compound
24 A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Intermittent Explosive Disorder (IED) Terminated NCT03420222 Phase 2 AVP-786;Placebo
25 N-Acetylcysteine in the Treatment of Deliberate Self-Harm in Adolescents: An Open Label Pilot Study Completed NCT01111734 Phase 1 fMRI
26 Effects of Non-invasive Brain on Decision-making in Impulse Control Disorders Unknown status NCT02927002
27 Psychosocial Risk- and Protective Factors of Secondary School Dropout in Luxembourg: an Exploratory Case-control Study Unknown status NCT01354236
28 Exploration of Mesocorticolimbic Pathway in Impulse Control Disorders in Parkinson's Disease: Study Using Tensor Diffusion Imaging and Tractography. Unknown status NCT02796040
29 Assessment of Longitudinal Functional Magnetic Resonance Imaging (fMRI) as a Brain Measure for Impulsivity in a Borderline Personality Disorder (BPD) Model Completed NCT02755181
30 A Cross-sectional, Retrospective Screening and Case-control Study Examining the Frequency of, and Risk Factors Associated With, Impulse Control Disorders in Parkinson's Disease Patients Treated With MIRAPEX® (Pramipexole) and Other Anti-parkinson Agents (DOMINION Study) Completed NCT00617019
31 Behavioural Addiction and Genetics in Parkinson's Disease Completed NCT02319395
32 Fingerprinting of Impulsivity in Four Diagnostic and Statistical Manual of Mental Disorders, Version 5 (DSM-5) Psychiatric Disorders That Have Been Clinically Associated With Impulsivity Using a Battery of Questionnaires and Behavioral Laboratory Tests Completed NCT02722174
33 Observational Study on Intrafamilial Oppositional Defiant Disorder (IODD) in Children and Adolescents Completed NCT03447535
34 Psychiatric and Cognitive Manifestations of Parkinson's Disease: A Prospective Cohort Study Completed NCT00360633
35 Cognitive Behavioral Treatment of Pediatric Trichotillomania Completed NCT00043563
36 Developing Online Response Inhibition Training for Individuals With Trichotillomania Completed NCT01984333
37 Behavior Therapy for Pediatric Trichotillomania Completed NCT00917098
38 Role of the Serotoninergic System in Impulse Control Disorders in Parkinson's Disease Recruiting NCT03970239 Positron Emission Tomography using [11 Carbon]-3-amino-4-(2-dimethylaminomethylphenylsulfanyl)-benzonitrile ([11C]-DASB) and [18 Fluorine]-altanserin ([18F]-altanserin);Positron Emission Tomography using [18 Fluorine]-altanserin ([18F]-altanserin)
39 Repetitive Transcranial Magnetic Stimulation (rTMS) of the Dorsolateral Prefrontal Cortex for the Treatment of Gambling Disorder: a Pilot Study Recruiting NCT03733808
40 Circadian Character of Food Compulsions and Impulses Control Disorders in Parkinsonian Patients With and Without Resting Leg Syndrome Not yet recruiting NCT03818243
41 Mapping Functional Networks of Brain Activity (Brain Network Activation, BNA) Based on Analysis of Evoked Response Potential (ERP) EEG Signals in Patients With Movement Disorders Not yet recruiting NCT03269201

Search NIH Clinical Center for Impulse Control Disorder

Cochrane evidence based reviews: disruptive, impulse control, and conduct disorders

Genetic Tests for Impulse Control Disorder

Anatomical Context for Impulse Control Disorder

MalaCards organs/tissues related to Impulse Control Disorder:

40
Brain, Skin, Cortex, Liver, Testes, Prefrontal Cortex, Subthalamic Nucleus

Publications for Impulse Control Disorder

Articles related to Impulse Control Disorder:

(show top 50) (show all 396)
# Title Authors PMID Year
1
Impulse control and related behaviors in Parkinson's disease with dementia. 61
32048392 2020
2
[Descriptive analysis of the admission of minors into a psychiatric unit]. 61
32386933 2020
3
Prevalence of comorbid psychiatric disorders among people with autism spectrum disorder: An umbrella review of systematic reviews and meta-analyses. 61
32203749 2020
4
Impulse control disorder-linked hypersexuality complicated by disseminated gonococcal infection in a patient with Parkinson's disease. 61
32139181 2020
5
Is RBD a risk factor for impulse control disorder in Parkinson's disease? 61
32468593 2020
6
A qualitative research of adolescents with behavioral problems about their experience in a dialectical behavior therapy skills training group. 61
32429886 2020
7
Kleptomania as a neglected disorder in psychiatry. 61
32401643 2020
8
Gambling and substance use: Comorbidity and treatment implications. 61
31881248 2020
9
Impulsivity Relates to Relative Preservation of Mesolimbic Connectivity in Patients with Parkinson Disease. 61
32361415 2020
10
Exploring Nonmotor Neuropsychiatric Manifestations of Parkinson Disease in a Comprehensive Care Setting. 61
32242493 2020
11
Validation of the Korean Version of the Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease Rating Scale. 61
32319241 2020
12
Functional inhibitory control dynamics in impulse control disorders in Parkinson's disease. 61
31710401 2020
13
Serial Cats Maiming Reveals Impulse Control Disorder Under Dopaminergic Agonists. 61
31970229 2020
14
Functional Analysis of the SIM1 Variant p.G715V in 2 Patients With Obesity. 61
31872862 2020
15
Long-Term Safety and Efficacy of Blonanserin Transdermal Patches in Japanese Patients with Schizophrenia: A 52-Week Open-Label, Multicenter Study. 61
31883082 2020
16
Trichotillomania is more related to Tourette disorder than to obsessive-compulsive disorder. 61
31576938 2020
17
Hypermethylation-associated downregulation of microRNA-4456 in hypersexual disorder with putative influence on oxytocin signalling: A DNA methylation analysis of miRNA genes. 61
31542994 2020
18
Response Inhibition and Emotional Regulation in the Patients with Attention-Deficit/Hyperactivity Disorder and Comorbidity of Disruptive, Impulse-Control, and Conduct Disorders. 61
31760718 2019
19
COPPADIS-2015 (COhort of Patients with PArkinson's DIsease in Spain, 2015): an ongoing global Parkinson's disease project about disease progression with more than 1000 subjects included. Results from the baseline evaluation. 61
31179586 2019
20
Prevalence of co-occurring mental health diagnoses in the autism population: a systematic review and meta-analysis. 61
31447415 2019
21
A Stage-Based Approach to Therapy in Parkinson's Disease. 61
31434341 2019
22
Dopamine Agonist-Induced Impulse Control Disorders in Patients With Prolactinoma: A Cross-Sectional Multicenter Study. 61
30848825 2019
23
Compulsive sexual behavior disorder in obsessive-compulsive disorder: Prevalence and associated comorbidity. 61
31079471 2019
24
Creativity related to dopaminergic treatment: A multicenter study. 61
30824283 2019
25
Imaging behavioural complications of Parkinson's disease. 61
28856542 2019
26
Prevalence of mental disorders in China: a cross-sectional epidemiological study. 61
30792114 2019
27
[Response inhibition and emotional responding in attention-deficit/hyperactivity disorder with comorbid disruptive, impulse-control, and conduct disorders]. 61
30692063 2019
28
Behavioural and trait changes in parkinsonian patients with impulse control disorder after switching from dopamine agonist to levodopa therapy: results of REIN-PD trial. 61
30361296 2019
29
Neuropsychiatric Traits Associated with Refractory Impulse Control Disorder in Parkinson's Disease. 61
32454490 2019
30
Behavioral and Neuroanatomical Account of Impulsivity in Parkinson's Disease. 61
31998210 2019
31
[Devotion to painting in a Parkinson's disease patient]. 61
30487358 2018
32
The Role of Atomoxetine for Parkinson Disease-Related Executive Dysfunction: A Systematic Review. 61
30346335 2018
33
A 7-year observation of the effect of subthalamic deep brain stimulation on impulse control disorder in patients with Parkinson's disease. 61
30054182 2018
34
Markers of impaired motor and cognitive volition in Parkinson's disease: Correlates of dopamine dysregulation syndrome, impulse control disorder, and dyskinesias. 61
29753604 2018
35
Sleep in Parkinson's Disease with Impulse Control Disorder. 61
30099617 2018
36
Psychotropic Polypharmacy Among Children and Youth Receiving Medicaid, 2012-2015. 61
30058983 2018
37
Psychological functioning in Parkinson's disease post-deep brain stimulation: Self-regulation and executive functioning. 61
29935753 2018
38
Spanish expert consensus on the use of safinamide in Parkinson's disease. 61
30072274 2018
39
Compulsive Sexual Behavior as an Impulse Control Disorder: Awaiting Field Studies Data. 61
29572770 2018
40
[The alexithymia questionnaire for children (AQC): Psychometric properties in a sample of 105 adolescents hospitalized in an adolescent psychiatric department]. 61
27745718 2018
41
Sleep and REM sleep behaviour disorder in Parkinson's disease with impulse control disorder. 61
29066517 2018
42
Markers of impaired motor and cognitive volition in Parkinson's disease: Correlates of dopamine dysregulation syndrome, impulse control disorder, and dyskinesias. 61
29198499 2018
43
Impulsivity in unaffected adolescent biological relatives of schizophrenia patients. 61
29175297 2018
44
Mechanisms Underlying Dopamine-Induced Risky Choice in Parkinson's Disease With and Without Depression (History). 61
30090860 2018
45
Deep Brain Stimulation of the Internal Globus Pallidus Improves Response Initiation and Proactive Inhibition in Patients With Parkinson's Disease. 61
29681869 2018
46
Safety and tolerability of IRL790 in Parkinson's disease with levodopa-induced dyskinesia-a phase 1b trial. 61
30534585 2018
47
Inducible nitric oxide synthase (NOS2) knockout mice as a model of trichotillomania. 61
29682419 2018
48
Recognizing Psychiatric Comorbidity With Reading Disorders. 61
29636707 2018
49
Impulse Control Disorders and Dopamine-Related Creativity: Pathogenesis and Mechanism, Short Review, and Hypothesis. 61
30574117 2018
50
Disruption of Multiple Distinctive Neural Networks Associated With Impulse Control Disorder in Parkinson's Disease. 61
30519167 2018

Variations for Impulse Control Disorder

Expression for Impulse Control Disorder

Search GEO for disease gene expression data for Impulse Control Disorder.

Pathways for Impulse Control Disorder

Pathways related to Impulse Control Disorder according to GeneCards Suite gene sharing:

(show all 22)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.03 SLC6A3 RTN4 MAOB MAOA DRD2 DRD1
2
Show member pathways
12.65 DRD5 DRD4 DRD3 DRD2 DRD1
3
Show member pathways
12.48 SLC6A3 MAOB MAOA DRD5 DRD4 DRD3
4 12.25 DRD5 DRD4 DRD3 DRD2 DRD1
6 12.17 HTR1A DRD5 DRD2 DRD1
7 12.03 SLC6A4 MAOA HTR2A HTR1A
8
Show member pathways
11.87 SLC6A3 MAOB MAOA DRD2 DRD1
9 11.83 SLC6A4 MAOB MAOA HTR2A HTR1A
10
Show member pathways
11.82 DRD4 DRD2 DRD1
11 11.78 HTR2A DRD4 DRD3
12
Show member pathways
11.77 DRD4 DRD3 DRD2
13 11.69 HTR2A DRD2 DRD1
14
Show member pathways
11.6 MAOB MAOA COMT
15
Show member pathways
11.54 HTR2A HTR1A DRD5 DRD4 DRD3 DRD2
16
Show member pathways
11.32 SLC6A4 SLC6A3 MAOA
17 11.07 SLC6A4 MAOA HTR2A HTR1A
18
Show member pathways
10.96 SLC6A4 SLC6A3 MAOA COMT
19
Show member pathways
10.84 MAOB MAOA COMT
20 10.76 MAOB MAOA COMT
21
Show member pathways
10.73 SLC6A4 SLC6A3 MAOB MAOA HTR1A DRD5
22
Show member pathways
10.69 MAOB MAOA

GO Terms for Impulse Control Disorder

Cellular components related to Impulse Control Disorder according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 membrane GO:0016020 10.39 SLITRK5 SLITRK1 SLC6A4 SLC6A3 RTN4 MAOB
2 integral component of membrane GO:0016021 10.31 SLITRK5 SLITRK1 SLC6A4 SLC6A3 RTN4 MAOB
3 plasma membrane GO:0005886 10.22 SLITRK5 SLITRK1 SLC6A4 SLC6A3 RTN4 HTR2A
4 integral component of plasma membrane GO:0005887 10.15 SLC6A4 SLC6A3 HTR2A HTR1A DRD5 DRD4
5 cell GO:0005623 10.11 RTN4 HTR2A GRN DRD5 DRD4 DRD3
6 cell junction GO:0030054 10.02 SLITRK1 SLC6A4 RTN4 HTR2A DRD1 DLGAP3
7 dendrite GO:0030425 9.91 HTR2A HTR1A DRD4 DRD2 DRD1 DNER
8 glutamatergic synapse GO:0098978 9.8 SLITRK1 HTR2A DRD4 DRD3 DRD2 DRD1
9 GABA-ergic synapse GO:0098982 9.78 SLITRK1 DRD3 DRD2 DRD1
10 ciliary membrane GO:0060170 9.71 DRD5 DRD2 DRD1
11 non-motile cilium GO:0097730 9.7 DRD5 DRD2 DRD1
12 dopaminergic synapse GO:0098691 9.63 SLC6A3 DRD3 DRD2
13 9+0 non-motile cilium GO:0097731 9.56 DRD5 DRD1
14 integral component of presynaptic membrane GO:0099056 9.55 SLC6A4 SLC6A3 HTR2A DRD2 DRD1
15 integral component of postsynaptic membrane GO:0099055 9.35 SLC6A4 SLC6A3 HTR2A DRD2 DRD1
16 synapse GO:0045202 9.32 SLITRK5 SLITRK1 SLC6A4 HTR2A HTR1A DRD5

Biological processes related to Impulse Control Disorder according to GeneCards Suite gene sharing:

(show top 50) (show all 76)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.35 HTR2A HTR1A GRN DRD5 DRD4 DRD3
2 G protein-coupled receptor signaling pathway GO:0007186 10.26 HTR2A HTR1A DRD5 DRD4 DRD3 DRD2
3 chemical synaptic transmission GO:0007268 10.05 SLITRK5 HTR2A HTR1A DRD5 DRD4
4 cell-cell signaling GO:0007267 10.03 DRD5 DRD3 DRD2 DRD1
5 response to ethanol GO:0045471 9.97 SLC6A3 MAOB DRD3 DRD2
6 cellular calcium ion homeostasis GO:0006874 9.96 HTR2A DRD5 DRD4 DRD3
7 response to toxic substance GO:0009636 9.94 SLC6A4 MAOB DRD3 DRD2
8 locomotory behavior GO:0007626 9.93 SLC6A3 DRD3 DRD2 DRD1
9 axonogenesis GO:0007409 9.92 SLITRK5 SLITRK1 DRD2
10 adenylate cyclase-modulating G protein-coupled receptor signaling pathway GO:0007188 9.92 DRD5 DRD3 DRD2 DRD1
11 response to drug GO:0042493 9.92 SLC6A4 SLC6A3 MAOB HTR2A DRD3 DRD2
12 memory GO:0007613 9.91 SLC6A4 HTR2A DRD1
13 learning GO:0007612 9.9 DRD3 DRD1 COMT
14 synapse assembly GO:0007416 9.9 SLITRK1 DRD2 DRD1 DNER
15 regulation of synaptic vesicle exocytosis GO:2000300 9.89 HTR2A DRD2 DRD1
16 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.89 HTR2A HTR1A DRD4 DRD1
17 social behavior GO:0035176 9.88 SLC6A4 DRD4 DRD3
18 visual learning GO:0008542 9.88 DRD3 DRD2 DRD1
19 positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G protein-coupled signaling pathway GO:0051482 9.87 DRD3 DRD2 DRD1
20 regulation of dopamine secretion GO:0014059 9.86 HTR2A DRD3 DRD2
21 adult behavior GO:0030534 9.85 SLITRK5 SLITRK1 DRD2
22 associative learning GO:0008306 9.85 DRD5 DRD2 DRD1
23 behavioral fear response GO:0001662 9.85 HTR1A DRD4 DRD1
24 G protein-coupled serotonin receptor signaling pathway GO:0098664 9.85 HTR2A HTR1A DRD4
25 response to cocaine GO:0042220 9.85 SLC6A3 DRD5 DRD3 DRD2 DRD1
26 negative regulation of blood pressure GO:0045776 9.84 DRD5 DRD3 DRD2
27 adenylate cyclase-activating adrenergic receptor signaling pathway GO:0071880 9.84 DRD5 DRD3 DRD2 DRD1
28 negative regulation of protein secretion GO:0050709 9.82 DRD4 DRD3 DRD2
29 arachidonic acid secretion GO:0050482 9.82 DRD4 DRD3 DRD2
30 prepulse inhibition GO:0060134 9.81 SLC6A3 DRD3 DRD2 DRD1
31 temperature homeostasis GO:0001659 9.8 HTR2A DRD2 DRD1
32 phospholipase C-activating dopamine receptor signaling pathway GO:0060158 9.8 DRD5 DRD3 DRD2 DRD1
33 negative regulation of voltage-gated calcium channel activity GO:1901386 9.79 DRD4 DRD3 DRD2
34 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.79 HTR2A DRD3 DRD2
35 behavioral response to ethanol GO:0048149 9.78 DRD4 DRD3 DRD2
36 grooming behavior GO:0007625 9.78 SLITRK5 HOXB8 DRD2 DRD1
37 response to amphetamine GO:0001975 9.77 DRD5 DRD4 DRD3 DRD2 DRD1
38 striatum development GO:0021756 9.76 SLITRK5 DRD2 DRD1
39 response to iron ion GO:0010039 9.75 SLC6A3 DRD2
40 negative regulation of cytosolic calcium ion concentration GO:0051481 9.75 DRD3 DRD2
41 long-term synaptic depression GO:0060292 9.75 DRD5 DRD1
42 vasoconstriction GO:0042310 9.75 SLC6A4 HTR1A
43 adenylate cyclase-activating dopamine receptor signaling pathway GO:0007191 9.75 DRD5 DRD3 DRD1
44 behavior GO:0007610 9.74 HTR2A HTR1A
45 neurotransmitter biosynthetic process GO:0042136 9.74 SLC6A4 SLC6A3
46 positive regulation of renal sodium excretion GO:0035815 9.74 DRD3 DRD2
47 G protein-coupled receptor internalization GO:0002031 9.74 DRD3 DRD2
48 regulation of postsynaptic neurotransmitter receptor internalization GO:0099149 9.74 DRD4 DRD3
49 neurotransmitter catabolic process GO:0042135 9.74 MAOB MAOA COMT
50 catecholamine metabolic process GO:0006584 9.73 MAOA COMT

Molecular functions related to Impulse Control Disorder according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.46 SLITRK5 SLITRK1 SLC6A4 SLC6A3 RTN4 MAOB
2 G protein-coupled receptor activity GO:0004930 9.98 HTR2A HTR1A DRD5 DRD4 DRD3 DRD2
3 neurotransmitter receptor activity GO:0030594 9.7 HTR2A HTR1A DRD4
4 drug binding GO:0008144 9.65 SLC6A3 HTR2A DRD4 DRD3 DRD2
5 G protein-coupled serotonin receptor activity GO:0004993 9.63 HTR2A HTR1A DRD4
6 serotonin binding GO:0051378 9.54 SLC6A4 HTR2A HTR1A
7 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.5 DRD4 DRD3 DRD2
8 monoamine transmembrane transporter activity GO:0008504 9.49 SLC6A4 SLC6A3
9 primary amine oxidase activity GO:0008131 9.48 MAOB MAOA
10 adrenergic receptor activity GO:0004935 9.46 DRD5 DRD3 DRD2 DRD1
11 dopamine neurotransmitter receptor activity, coupled via Gs GO:0001588 9.4 DRD5 DRD1
12 dopamine neurotransmitter receptor activity GO:0004952 9.35 DRD5 DRD4 DRD3 DRD2 DRD1
13 dopamine binding GO:0035240 9.1 SLC6A3 DRD5 DRD4 DRD3 DRD2 DRD1

Sources for Impulse Control Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....